Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Teemu Natunen"'
Autor:
Ahmed B. Montaser, Janita Kuiri, Teemu Natunen, Pavel Hruška, David Potěšil, Seppo Auriola, Mikko Hiltunen, Tetsuya Terasaki, Marko Lehtonen, Aaro Jalkanen, Kristiina M. Huttunen
Publikováno v:
Life sciences. 310
Neuroinflammation is a prominent hallmark in several neurodegenerative diseases (NDs). Halting neuroinflammation can slow down the progression of NDs. Improving the efficacy of clinically available non-steroidal anti-inflammatory drugs (NSAIDs) is a
Autor:
Jenni, Kyyriäinen, Natallie, Kajevu, Ivette, Bañuelos, Leonardo, Lara, Anssi, Lipponen, Silvia, Balosso, Elina, Hämäläinen, Shalini, Das Gupta, Noora, Puhakka, Teemu, Natunen, Teresa, Ravizza, Annamaria, Vezzani, Mikko, Hiltunen, Asla, Pitkänen
Publikováno v:
International Journal of Molecular Sciences, Vol 22, Iss 10555, p 10555 (2021)
International Journal of Molecular Sciences
Volume 22
Issue 19
International Journal of Molecular Sciences
Volume 22
Issue 19
We assessed the effect of antioxidant therapy using the Food and Drug Administration-approved respiratory drug N-acetylcysteine (NAC) or sulforaphane (SFN) as monotherapies or duotherapy in vitro in neuron-BV2 microglial co-cultures and validated the
Autor:
Nadine Huber, Dorit Hoffmann, Raisa Giniatullina, Hannah Rostalski, Stina Leskelä, Mari Takalo, Teemu Natunen, Eino Solje, Anne M. Remes, Rashid Giniatullin, Mikko Hiltunen, Annakaisa Haapasalo
Publikováno v:
Neurobiology of Disease, Vol 162, Iss, Pp 105584-(2022)
Frontotemporal lobar degeneration (FTLD) comprises a heterogenous group of progressive neurodegenerative syndromes. To date, no validated biomarkers or effective disease-modifying therapies exist for the different clinical or genetic subtypes of FTLD
Autor:
Petteri Stenroos, Tiina Pirttimäki, Jaakko Paasonen, Ekaterina Paasonen, Raimo A Salo, Hennariikka Koivisto, Teemu Natunen, Petra Mäkinen, Teemu Kuulasmaa, Mikko Hiltunen, Heikki Tanila, Olli Gröhn
Publikováno v:
NeuroImage, Vol 234, Iss, Pp 117987-(2021)
Isoflurane, the most commonly used preclinical anesthetic, induces brain plasticity and long-term cellular and molecular changes leading to behavioral and/or cognitive consequences. These changes are most likely associated with network-level changes
Autor:
Luukas Leppänen, Petra Mäkinen, Helena Svobodova, Simo Ryhänen, Teemu Natunen, Jussi Pihlajamäki, Mikael Marttinen, Heikki Tanila, Sisko Juutinen, Teemu Kuulasmaa, Sami Gabbouj, Mikko Hiltunen, Annakaisa Haapasalo, Henna Martiskainen, Mari Takalo, Benjam Kemiläinen, Susanna Kemppainen, Ville Leinonen, Hennariikka Koivisto, Satu Kaipainen, Tuomas Rauramaa, Eija Rahunen, Pasi Miettinen
Publikováno v:
Molecular Neurodegeneration
Molecular Neurodegeneration, Vol 15, Iss 1, Pp 1-30 (2020)
Molecular Neurodegeneration, Vol 15, Iss 1, Pp 1-30 (2020)
BackgroundAlzheimer’s disease (AD) is the most common neurodegenerative disease and type 2 diabetes (T2D) plays an important role in conferring the risk for AD. Although AD and T2D share common features, the common molecular mechanisms underlying t
Publikováno v:
Basic & Clinical Pharmacology & Toxicology. 124:40-49
Prolyl oligopeptidase (PREP) is an abundant peptidase in the brain and periphery, but its physiological functions are still largely unknown. Recent findings point to a role for PREP in inflammatory processes. This study assessed the cellular and extr
Autor:
Nadine Huber, Kirsi Rilla, Mikko Hiltunen, Kaisa M. A. Paldanius, Paavo Honkakoski, Annakaisa Haapasalo, Mari Takalo, Stina Leskelä, Mikko T. Huuskonen, Hiramani Dhungana, Jari Koistinaho, Pirta Hotulainen, Hilkka Soininen, Petra Mäkinen, Enni Bertling, Mikael Marttinen, Teemu Natunen, Tarja Malm, Henna Martiskainen
Publikováno v:
Journal of Neuroinflammation, Vol 14, Iss 1, Pp 1-16 (2017)
Journal of Neuroinflammation
Journal of Neuroinflammation
Background DHCR24, involved in the de novo synthesis of cholesterol and protection of neuronal cells against different stress conditions, has been shown to be selectively downregulated in neurons of the affected brain areas in Alzheimer’s disease.
Autor:
Mari Takalo, Juha-Pekka Pursiheimo, Jussi Paananen, Tiina Pirttimäki, Eino Solje, Heikki Tanila, Tuomas Rauramaa, Pasi Miettinen, Sami Gabbouj, Rudolph E. Tanzi, Ville Leinonen, Stina Leskelä, Timo Sarajärvi, Teemu Natunen, Mitja I. Kurki, Mikko Hiltunen, Jayashree Viswanathan, Susanna Kemppainen, Annakaisa Haapasalo, Mikael Marttinen, Eveliina Tahvanainen, Kaisa M.A. Kurkinen, Kari J. Airenne, Hilkka Soininen, Petra Mäkinen
Publikováno v:
Neurobiology of Disease, Vol 85, Iss, Pp 187-205 (2016)
Accumulation of β-amyloid (Aβ) and phosphorylated tau in the brain are central events underlying Alzheimer's disease (AD) pathogenesis. Aβ is generated from amyloid precursor protein (APP) by β-site APP-cleaving enzyme 1 (BACE1) and γ-secretase-
Autor:
Maria Jäntti, Virpi Talman, Raimo K. Tuominen, Kaisa M. A. Paldanius, Teemu Natunen, Mikko Hiltunen, Petra Mäkinen, J.C. Wu, Timo Sarajärvi, Ilari Tarvainen
Publikováno v:
Neuropharmacology. 141
Abnormal protein kinase C (PKC) function contributes to many pathophysiological processes relevant for Alzheimer's disease (AD), such as amyloid precursor protein (APP) processing. Phorbol esters and other PKC activators have been demonstrated to enh
Autor:
Tarja Malm, Asla Pitkänen, Mikko Hiltunen, Teemu Natunen, Joana I. Soares, Xavier Ekolle Ndode-Ekane, Pedro Andrade, Jukka Sallinen, Jari Nissinen, Katja M. Kanninen, Olena Shatillo
Publikováno v:
Epilepsy research. 136
Treatment of TBI remains a major unmet medical need, with 2.5 million new cases of traumatic brain injury (TBI) each year in Europe and 1.5 million in the USA. This single-center proof-of-concept preclinical study tested the hypothesis that pharmacol